(Q38023902)

27 August 2017

title

Sclerostin: a possible target for the management of cancer-induced bone disease (English)

1 reference

27 August 2017

Efstathios Kastritis

3

0 references

Athanasios Dimopoulos

Meletios A Dimopoulos

2

0 references

Maria Gkotzamanidou

1

Maria Gkotzamanidou

1 reference

27 August 2017

6

Evangelos Terpos

1 reference

27 August 2017

Lia Angela Moulopoulos

5

Lia A Moulopoulos

1 reference

27 August 2017

Dimitrios Christoulas

4

Dimitrios Christoulas

1 reference

27 August 2017

language of work or name

English

0 references

publication date

5 July 2012

1 reference

Expert Opinion on Therapeutic Targets

27 August 2017

published in

1 reference

27 August 2017

volume

16

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

761-769

1 reference

Sclerostin: current knowledge and future perspectives

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Metastasis and bone loss: advancing treatment and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Myeloma bone disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Bone quality--the material and structural basis of bone strength and fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Osteocyte: the unrecognized side of bone tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Matrix mineralization as a trigger for osteocyte maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Osteocytes, mechanosensing and Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Sclerostin binds and regulates the activity of cysteine-rich protein 61.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

The sclerostin-bone protein interactome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Sclerostin and Dickkopf-1 in renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Relation of age, gender, and bone mass to circulating sclerostin levels in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Signaling pathways in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Aberrant WNT/β-catenin signaling in parathyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Wnt signaling in stem and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

The Wnt/beta-catenin pathway in adrenocortical development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Wnt/β-catenin activation promotes prostate tumor progression in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Implications of bone metastases and the benefits of bone-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Advances in the biology of bone metastasis: how the skeleton affects tumor behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

The prognostic significance of BMP-6 signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Advances in imaging and the management of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.697154

10.1517/14728222.2012.697154

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference